SVB Leerink Cuts Paratek Pharmaceuticals (NASDAQ:PRTK) Price Target to $14.00

Paratek Pharmaceuticals (NASDAQ:PRTK) had its target price trimmed by SVB Leerink from $15.00 to $14.00 in a research note issued to investors on Tuesday morning, BenzingaRatingsTable reports. The firm currently has an outperform rating on the specialty pharmaceutical company’s stock.

Several other research firms have also commented on PRTK. Zacks Investment Research upgraded shares of Paratek Pharmaceuticals from a hold rating to a buy rating and set a $5.25 price target on the stock in a report on Friday, July 24th. ValuEngine raised Paratek Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $15.71.

PRTK traded up $0.05 during trading on Tuesday, hitting $4.28. The stock had a trading volume of 8,302 shares, compared to its average volume of 725,951. The stock has a 50 day simple moving average of $4.80 and a two-hundred day simple moving average of $4.24. The company has a market capitalization of $191.99 million, a PE ratio of -1.21 and a beta of 1.45. Paratek Pharmaceuticals has a twelve month low of $2.50 and a twelve month high of $6.41.

Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its earnings results on Monday, August 10th. The specialty pharmaceutical company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.39). On average, sell-side analysts anticipate that Paratek Pharmaceuticals will post -1.94 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRTK. Nuveen Asset Management LLC lifted its stake in shares of Paratek Pharmaceuticals by 82.2% in the 1st quarter. Nuveen Asset Management LLC now owns 193,457 shares of the specialty pharmaceutical company’s stock valued at $610,000 after purchasing an additional 87,258 shares during the period. BNP Paribas Arbitrage SA grew its holdings in Paratek Pharmaceuticals by 121.2% during the first quarter. BNP Paribas Arbitrage SA now owns 10,164 shares of the specialty pharmaceutical company’s stock valued at $32,000 after purchasing an additional 5,570 shares during the period. Alliancebernstein L.P. boosted its holdings in shares of Paratek Pharmaceuticals by 21.8% in the first quarter. Alliancebernstein L.P. now owns 56,400 shares of the specialty pharmaceutical company’s stock worth $178,000 after acquiring an additional 10,100 shares during the period. Balyasny Asset Management LLC bought a new position in shares of Paratek Pharmaceuticals in the first quarter worth $1,071,000. Finally, Citigroup Inc. boosted its holdings in shares of Paratek Pharmaceuticals by 32.2% in the first quarter. Citigroup Inc. now owns 14,227 shares of the specialty pharmaceutical company’s stock worth $45,000 after acquiring an additional 3,469 shares during the period. Hedge funds and other institutional investors own 43.33% of the company’s stock.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris.

Further Reading: Calculate Your Return on Investment (ROI)

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.